- Home
- SHOT vs CUE Comparison
SHOT vs CUE Comparison
Compare SHOT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- CUE
- Stock Information
- Founded
- SHOT 2018
- CUE 2014
- Country
- SHOT United States
- CUE United States
- Employees
- SHOT N/A
- CUE N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- CUE Health Care
- Exchange
- SHOT Nasdaq
- CUE Nasdaq
- Market Cap
- SHOT 30.4M
- CUE 48.0M
- IPO Year
- SHOT 2020
- CUE 2018
- Fundamental
- Price
- SHOT $0.43
- CUE $0.74
- Analyst Decision
- SHOT
- CUE Strong Buy
- Analyst Count
- SHOT 0
- CUE 3
- Target Price
- SHOT N/A
- CUE $3.00
- AVG Volume (30 Days)
- SHOT 6.3M
- CUE 323.3K
- Earning Date
- SHOT 08-13-2025
- CUE 08-13-2025
- Dividend Yield
- SHOT N/A
- CUE N/A
- EPS Growth
- SHOT N/A
- CUE N/A
- EPS
- SHOT N/A
- CUE N/A
- Revenue
- SHOT $573,336.00
- CUE $7,991,000.00
- Revenue This Year
- SHOT N/A
- CUE N/A
- Revenue Next Year
- SHOT N/A
- CUE $23.84
- P/E Ratio
- SHOT N/A
- CUE N/A
- Revenue Growth
- SHOT 69.32
- CUE 13.83
- 52 Week Low
- SHOT $0.23
- CUE $0.45
- 52 Week High
- SHOT $1.77
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SHOT 54.76
- CUE 51.10
- Support Level
- SHOT $0.35
- CUE $0.65
- Resistance Level
- SHOT $0.48
- CUE $0.83
- Average True Range (ATR)
- SHOT 0.06
- CUE 0.07
- MACD
- SHOT 0.01
- CUE 0.01
- Stochastic Oscillator
- SHOT 46.94
- CUE 30.43
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.